Reduces risk for heart failure and cardiovascular disease hospitalizations.
Diabetes Type 2
Noteworthy diabetes management products and updates making waves this year.
Now approved for risk reductions in patients with type 2 diabetes mellitus.
Now approved in 7mg and 14 mg tablets.
First non-insulin drug for pediatric use approved in nearly 20 years.
Type 2 diabetes mellitus is a risk factor for incident heart failure, according to a new scientific statement from the American Heart Association (AHA), and it increases the risk of morbidity and mortality in patients with established disease.
New drug combines dapagliflozin, saxagliptin, and metformin.
Results from a recent ELLIPSE trial indicate superiority in reducing blood sugar when compared to the placebo.